Loading…
Cytokinetics, Incorporated is projected to rise to $110.07 by 2027, a +30% move from its current price of $84.87. CYTK is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 12 | $83.26 | $84.91 | $86.59 | +0.04% |
| Jul 13 | $82.62 | $84.94 | $87.33 | +0.08% |
| Jul 14 | $82.14 | $84.98 | $87.91 | +0.12% |
| Jul 15 | $81.74 | $85.01 | $88.41 | +0.17% |
| Jul 16 | $81.40 | $85.05 | $88.86 | +0.21% |
| Jul 17 | $81.09 | $85.08 | $89.27 | +0.25% |
| Jul 18 | $80.81 | $85.12 | $89.65 | +0.29% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $80.81 | $85.12 | $89.65 | +0.29% |
| Week 2 | $79.32 | $85.36 | $91.87 | +0.58% |
| Week 3 | $78.25 | $85.61 | $93.67 | +0.88% |
| Week 4 | $77.40 | $85.86 | $95.26 | +1.17% |
| Week 5 | $76.68 | $86.11 | $96.71 | +1.46% |
| Week 6 | $76.05 | $86.36 | $98.07 | +1.76% |
| Week 7 | $75.50 | $86.61 | $99.36 | +2.06% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Cytokinetics, Incorporated is a healthcare company focused on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction.
In addition, the company is involved in developing Ulacamten, a novel, selective, oral, and small molecule cardiac myosin inhibitor designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction in Phase 1 clinical trials; and CK-089, a fast skeletal muscle troponin activator in Phase 1 clinical trials. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.
Cytokinetics, Incorporated (CYTK) is a healthcare stock with a current price of $87.26 and a market cap of $11.85B, ranking 816. The stock trades amid a bullish near-term posture, with a 30-day range of $74.69 to $101.95 and a price setup that places resistance at $87.26 and support at $67.07. The latest price level sits near the 50-day moving average at $72.87, above the 200-day moving average of $64.63, signaling a constructive trend in the near term.
A major floor 29.8% below — a decisive break under it would weaken the trend.
The nearest floor, 21.0% below — buyers have tended to step in here.
Price is pressing into resistance (2.8% away) — a breakout level to watch.
A major ceiling 17.7% above — clearing it would confirm fresh momentum.
Key CYTK support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of CYTK market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $85.39 | Sell | $85.26 | Sell |
| MA 10 | $85.33 | Sell | $84.33 | Buy |
| MA 20 | $80.87 | Buy | $81.75 | Buy |
| MA 50 | $76.19 | Buy | $76.75 | Buy |
| MA 100 | $70.11 | Buy | $72.01 | Buy |
| MA 200 | $66.06 | Buy | $65.78 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 63.17 | Neutral |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | 59.30 | Neutral |
| Williams %R (14) | -29.54 | Info |
| MACD (12,26,9) | 0.15 | Buy |
| ROC (12) | 6.07 | Buy |
| Bollinger %B (20,2) | 0.68 | Neutral |
| Stochastic %K (14) | 70.46 | Neutral |
| TRIX (15) | 0.60 | Buy |
| Awesome (5,34) | 7.69 | Buy |
| Ultimate (7,14,28) | 54.87 | Neutral |
| Momentum (10) | 4.07 | Buy |
| Aroon Osc (25) | 48.00 | Buy |
| Hull MA (9) | 85.30 | Sell |
| ADX (14) | 28.88 | Buy |
| ATR (14) | 1.34 | Info |
The 30-day range for CYTK is $74.69 to $101.95, indicating a broad trading band over the period. RSI14 sits at 80, pointing to strong momentum in the current swing. The stock trades above the SMA50 of $72.87 and above the SMA200 of $64.63, with clear support at $67.07 and congestion resistance at $87.26.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $59.58 | $84.87 | $114.32 | 0% | Neutral | |
| $89.91 | $110.07 | $141.04 | +30% | Bullish | |
| $102.18 | $127.54 | $168.02 | +50% | Bullish | |
| $107.51 | $136.36 | $183.59 | +61% | Bullish | |
| $119.24 | $153.37 | $210.35 | +81% | Bullish | |
| $148.90 | $193.97 | $270.39 | +129% | Bullish | |
| $171.38 | $225.89 | $319.52 | +166% | Bullish | |
| $190.58 | $253.97 | $364.04 | +199% | Bullish | |
| $204.53 | $275.40 | $399.64 | +225% | Bullish | |
| $208.53 | $283.58 | $416.23 | +234% | Bullish | |
| $341.99 | $486.09 | $748.78 | +473% | Bullish | |
| $701.11 | $1,072.72 | $1,774.99 | +11.6x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $59.58 | $84.87 | $101.74 | +0.00% |
| August 2026 | $73.41 | $86.01 | $103.01 | +1.34% |
| September 2026 | $74.86 | $88.14 | $106.42 | +2.48% |
| October 2026 | $77.26 | $91.36 | $111.05 | +3.64% |
| November 2026 | $77.54 | $92.02 | $112.49 | +0.73% |
| December 2026 | $78.12 | $93.02 | $114.32 | +1.09% |
Click any year to see its month-by-month CYTK forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Cytokinetics, Incorporated's 2026 outlook centres on $84.87, within a $59.58 to $114.32 range. That marks a 0% change versus current levels. Price action looks broadly range-bound.
By 2027, CYTK could reach as high as $141.04, with a base case around $110.07 and support toward $89.91 — roughly +30% from $84.87. Buyers look set to stay in control over this stretch.
Expect CYTK to range from $102.18 to $168.02 through 2028. The $127.54 average target implies a +50% move from current prices. That is up +16% on the projected 2027 average. Momentum favours further upside here.
The CYTK price prediction for 2029 points to an average of $136.36 (low $107.51, high $183.59) — a potential gain of +61% on today's $84.87. Buyers look set to stay in control over this stretch.
In 2030, CYTK is projected to trade between $119.24 and $210.35, averaging $153.37 — a potential gain of +81% from today's $84.87. That is up +12% on the projected 2029 average. Momentum favours further upside here.
Cytokinetics, Incorporated's 2031 outlook centres on $193.97, within a $148.90 to $270.39 range. That is up +26% on the projected 2030 average. That marks a +129% change versus current levels. Buyers look set to stay in control over this stretch.
By 2032, CYTK could reach as high as $319.52, with a base case around $225.89 and support toward $171.38 — roughly +166% from $84.87. Momentum favours further upside here.
Expect CYTK to range from $190.58 to $364.04 through 2033. The $253.97 average target implies a +199% move from current prices. That is up +12% on the projected 2032 average. Buyers look set to stay in control over this stretch.
The CYTK price prediction for 2034 points to an average of $275.40 (low $204.53, high $399.64) — a potential gain of +225% on today's $84.87. Momentum favours further upside here.
In 2035, CYTK is projected to trade between $208.53 and $416.23, averaging $283.58 — a potential gain of +234% from today's $84.87. That is up +3% on the projected 2034 average. Buyers look set to stay in control over this stretch.
Cytokinetics, Incorporated's 2040 outlook centres on $486.09, within a $341.99 to $748.78 range. That is up +71% on the projected 2035 average. That marks a +473% change versus current levels. Momentum favours further upside here.
By 2050, CYTK could reach as high as $1,774.99, with a base case around $1,072.72 and support toward $701.11 — roughly +11.6x from $84.87. Buyers look set to stay in control over this stretch.
Investing $1,000 in CYTK today (≈ 11.782727 CYTK) could be worth
$12,639.58
+$11,639.58 (+1164%) by 2050 · US Dollar
Based on the average projected CYTK price of $1,072.72 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in CYTKwould be worth at today's price.
$1,000 invested in CYTK on Jul 10, 2025 (≈ 27.329871 CYTK) would be worth
$2,319.49
+$1,319.49 (+131.9%) today · 2.32× · US Dollar
Based on a CYTK entry price of $36.59 vs. today's $84.87.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $86.49 | $981.27 | -1.9% |
| 1 month ago | $67.07 | $1,265.39 | +26.5% |
| 3 months ago | $65.01 | $1,305.49 | +30.5% |
| 6 months ago | $64.64 | $1,312.96 | +31.3% |
| 1 year ago | $36.59 | $2,319.49 | +131.9% |
| All time (5.0y) ago | $19.25 | $4,408.83 | +340.9% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our CYTK forecast.
Our base-case forecast reaches $170.00 around 2031.
Implied market cap at $170.00: $23.08B
The multi-year forecast shows bullish momentum beginning in 2027 and extending through 2050. The 2026 forecast has an average price of $87.26 with a minimum of $59.58 and a maximum of $120.45, and a neutral sentiment. By 2030 the average price rises to $154.06 with a maximum of $218.05 and a 76.6 ROI, continuing a bullish trajectory.
The 2040 forecast projects an average of $470.30 (maximum $761.01) with a 439 ROI and bullish sentiment, and 2050 projects an average of $1,051.76 (maximum $1,846.32) with a 1105.3 ROI and bullish sentiment. These figures imply substantial upside over the long term, but they are estimates and not guarantees; actual results could differ.
Tap a question to reveal the answer.
2030 forecast shows a minimum of $116.83, an average of $154.06, and a maximum of $218.05 with a ROI of 76.6 and sentiment BULLISH.
Forecasts from 2027 onward show a bullish path with higher averages (e.g., 2030 average $154.06) and positive ROI values (e.g., 76.6 in 2030, 439 in 2040, 1105.3 in 2050) and bullish sentiment, though these are estimates and not guarantees.
Yes. The 2050 forecast lists an average price of $1,051.76 and a maximum of $1,846.32 with a 1105.3 ROI and bullish sentiment.
The current price is $87.26.
The 30-day range is $74.69 to $101.95.
Cytokinetics, Incorporated Community Discussion
0Share your Cytokinetics, Incorporated price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.